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Background and Objectives. Impaired microcirculation during the chronic stage of complex regional pain syndrome (CRPS) is
related to increased vasoconstriction, tissue hypoxia, and metabolic tissue acidosis in the aﬀected limb. Endothelial dysfunction
is suggested to be the main cause of diminished blood ﬂow. The aim of this study was to examine the distribution of endothelial
nitric oxide synthase (eNOS) and endothelin-1(ET-1) relative to vascular density represented by the endothelial marker CD31-
immunoreactivity in the skin tissue of patients with chronic CRPS. Methods. We performed immunohistochemical staining on
sections of skin specimens obtained from the amputated limbs (one arm and one leg) of two patients with CRPS. Results.I n
comparison to proximal specimens we found an increased number of migrated endothelial cells as well as an increase of eNOS
activity in distal dermis specimens. Conclusions. We found indications that endothelial dysfunction plays a role in chronic CRPS.
Copyright © 2008 J. George Groeneweg et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Complex regional pain syndrome 1 (CRPS) is deﬁned as “a
syndrome in which the central nervous system representa-
tions of the somatosensory, somatomotor, and sympathetic
systems are altered concomitantly with important peripheral
changes such as edema, signs of inﬂammation, sympathetic-
aﬀerent coupling, and trophic changes” [1]. The manner
in which the peripheral and central changes interact is
only partly understood [1]. During the chronic stage of
CRPS,increasedvasoconstriction[2],tissuehypoxia[3],and
metabolictissueacidosis[4,5]indicatethatmicrocirculation
is impaired, which aﬀects the nutritive blood ﬂow in
superﬁcial and deep tissues [6, 7].
The endothelium modulates vascular tone by releasing
endothelium-derived vasodilators including nitric oxide
(NO), prostacyclin, bradykinin, and endothelium-derived
hyperpolarizing factor; and vasoconstrictors, such as
endothelin-1 (ET-1) and angiotensin II, in response to a
number of biochemical and physical stimuli [8]. Growing
evidence [9] suggests that endothelial dysfunction is the
main cause of diminished blood ﬂow in chronic cold CRPS.
Although numerous papers about CRPS have been
published since its ﬁrst description in 1545 [10], literature
regarding the associated pathological alterations in blood
vessels is scarce. The few papers on this topic describe
clearly visible abnormalities of the entire microvascular
system, including an increase in the number of capillaries
[11, 12], endothelial swelling, and changes in the vessel
laminal wall [13]. The impressive capillary changes range
from severely thickened basal membrane with intimal vac-
uolization, perivascular edema, and debris from pericytes
between the basal membrane layers, to necrosis [14, 15].
Greatly thickened multilaminated walls were found, consid-
erably reducing the inner diameter of the vessel [12, 16].
Endothelial cells with a shrunken appearance and capillaries
withonlyendothelialcelldebrisintheluminawereobserved,
while other capillaries could be traced by the thickened
basal membrane only, lacking the presence of other cellular
remnants [15].2 Mediators of Inﬂammation
Histochemicalprocedures[17]andimmunoﬂuorescence
[16] have been used to investigate the distribution of
cutaneous nerve ﬁbers, but there are no reports of using
immunohistochemical staining to evaluate endothelial dys-
function in CRPS. Key elements in the function of the
endothelium are NO and ET-1. The loss of endothelium-
dependent NO mediated vasodilation occurs early during
endothelial dysfunction [18]. Since NO has a half-life time
of only 3–5 seconds [19], we measured endothelial nitric
oxide synthase (eNOS), which is a constitutional endothelial
cell enzyme that produces NO from L-arginine. Increased
production and/or activity of ET-1 may participate in several
pathologic states related to a dysfunctional endothelium
[20].
The aim of this study was to examine the distribution of
eNOS and ET-1 in relation to vascular density represented
by the endothelial marker CD31-immunoreactivity in skin
tissue from amputated limbs of patients with CRPS.
2. METHODS
2.1. Patients
Human tissue was obtained from the surgically amputated
extremities of two patients diagnosed with CRPS type 1,
according to the Bruehl diagnostic criteria [21], at the Pain
Treatment Centre of the Erasmus MC. Both patients gave
written informed consent prior to the amputation. A lower
limb was amputated in patient A and an upper limb in
patient B. Skin samples, harvested immediately following the
amputations, were taken from the dorsal side of the foot of
patient A and from the dorsal side of the hand of patient
B; both of these samples were categorized as distal tissue
samples. Proximal tissue samples were harvested from near
the cutting face, taking tissue that appeared to be the least
diseased.
Patient A was a 46-year-old female who developed CRPS
in her right leg after an electromyography recording in
1996. One year later, symptoms appeared in the left leg,
and in 1998, in her right hand. The patients’ complaints
persisted and despite intense rehabilitation, both legs and
the right hand became nonfunctional. There was edema in
both legs, and there were severe contractures and pain in
the legs and hand. Walking was impossible and she relied
on a wheelchair for transport. During a visit to our clinic
in 2003, muscle force, reﬂexes, and coordination could not
be tested and there was hyperesthesia in both legs and
the hand. She was treated with paracetamol, amitriptyline,
durogesic, mannitol, and baclofen, and received an epidural
block with marcaine and fentanyl. Due to continuous
infections (erisipelas) in both legs in June 2003, antibiotics
were prescribed but the infections were resistant to therapy.
Therefore, the left leg had to be amputated in October 2003,
followedbytherightlegoneweeklater.Postoperativehealing
was complicated by pressure ulcers and she was released
from the hospital using paracetamol and tramadol for pain
control. A video thermographic recording was not made, but
the examining physician described both legs as very cold.
Patient B was a 38-year-old female who developed CRPS
in the right hand in December 2002 as a consequence of
a metacarpal II fracture. After 10 days in a plaster cast,
she showed severe symptoms of CRPS with pain, edema,
and contractures. Despite extensive pharmacotherapy to
reduce pain and inﬂammation, improve peripheral blood
ﬂow, and relieve the spasticity, the patient developed severe
dystonia in the right hand. The dystonia and pain made
conventional nail care impossible; therefore, nail clipping
was performed under general anesthesia every few months.
The patient had contractures in her wrist and ﬁngers,
spasms of the musculature, burning pain, allodynia and
hyperalgesia, edema, increased transpiration, excessive hair
growth, and a darker skin color on the aﬀected limb. A
video thermographic recording [22, 23] showed that the
CRPS extremity was 6.5◦C colder than the contralateral
unaﬀected control. Shoulder functioning was normal. Spinal
cord trial stimulation in February 2004 was not successful.
At the request of the patient, who could no longer cope
with the burden of frequent general anesthesia, upper arm
amputation was performed in May 2006. There were no
postoperative complications and the patient experienced a
dramatic reduction in pain.
2.2. Immunohistochemicalstainingfor
CD31andeNOS
In order to demonstrate the vascular state of the CRPS
skin tissues, the endothelial marker CD31 was visualized by
immunoreactive (IR) staining.
Frozen skin tissue samples were cut in serial 6μm
sections, transferred to poly-L-lysine-coated microscope
slides (Menzel-Glaser, Omnilabo, Breda, the Netherlands),
air dried, and stored at −80◦C. For immunohistochemical
staining, sections were thawed, ﬁxed in acetone for 10
minutes, and rinsed with phosphate buﬀer saline (PBS,
pH 7.8). The staining procedure was conducted in a half-
automatic stainer (Sequenza, Shandon Scientiﬁc, Zeist, the
Netherlands). The slides were incubated with 10% normal
goat serum (NGS; Sanquin, Amsterdam, the Netherlands)
for 10 minutes and then with primary mouse antihuman
antibodiesagainstCD31(JC/70ADako,Glostrup,Denmark)
or eNOS (SA-258 BIOMOL International L.P., Exeter, UK)
for 60 minutes. Both antibodies had been diluted in
1% blocking buﬀer (Blocking Reagent, Roche Diagnostics
GmbH, and Mannheim, Germany). After each incubation
step, the slides were rinsed with PBS for 5 minutes. After
incubation with the primary antibodies, sections were rinsed
and incubated with biotinylated goat antimouse antibodies
(BioGenex, Klinipath, Duiven, the Netherlands) and 10%
normal human serum (NHS; Sanquin) for 30 minutes. This
step was followed by incubation with alkaline phosphatase-
conjugatedstreptavidin(Biogenex,Klinipath)and10%NHS
for another 30 minutes. Slides were rinsed with both PBS
and TRIS buﬀers (TRIS HCl 0.1mol/L, pH 8.5), and then
incubated with new fuchsine substrate (Chroma, Kongen,
Germany) diluted in TRIS buﬀer. Finally, the sections were
washed with PBS, counterstained with Gill’s hematoxylin
(Merck, Darmstadt, Germany) for 30 seconds, rinsed withJ. George Groeneweg et al. 3
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Figure 1: (a) CD31-immunoreactive vessels in skin tissue from the amputated arm of CRPS patient A. CD31-positive blood vessels are
stained red. (b) eNOS staining of a serial section. eNOS-positive blood vessels are stained red.
tap water, dried, and embedded in VectaMount (Vector,
Burlingame, Calif, USA).
2.3. Immunohistochemicaldoublestainingfor
ET-1andCD31
After ﬁxing in acetone and washing with PBS, endogenous
peroxidase was blocked with 0.1% sodium azide and 0.03%
hydrogen peroxide in PBS for 30 minutes. Sections were
rinsed and incubated with 10% NGS for 10 minutes, fol-
lowed by incubation with rat antihuman ET-1 (3G10, R&D
systems, Abingdon, UK) for 60 minutes. The sections were
rinsed and incubated with goat antirat antibody conjugated
with alkaline phosphatase (Sigma, St. Louis, Mo, USA) and
10% NHS for 30 minutes. Thereafter, the slides were rinsed
and incubated with mouse antihuman CD31 for 60 minutes.
Then sections were rinsed and incubated with biotinylated
goat antimouse antibodies and 10% normal human serum
(NHS) and 10% normal rat serum (Sanquin) for 30 minutes.
After washing, the slides were incubated with streptavidin-
conjugated peroxidase (Biogenex, Klinipath) and 10% NHS
for another 30 minutes. After rinsing with PBS and substrate
TRIS buﬀer, slides were incubated for 30 minutes in fast
blue substrate (Sigma). Finally, sections were rinsed and
incubated with peroxidase nova red substrate (Vector) for 5
minutes, rinsed with PBS, and embedded in VectaMount.
2.4. Quantiﬁcationoftheimmunoreaction
ENOS and CD31 staining was performed on adjacent slides
of serial sections. Slides were examined using a Leica
microscope ﬁxed with a Leica DC500 camera for digitizing
images. Semiquantitative evaluation of the diﬀerent markers
was performed by counting the number of positive blood
vessels in the dermis of two sections each from both the
distalandproximalspecimens.Aftermeasuringthetotalarea
of the dermis using the Leica imaging analysis system, the
number of positive blood vessels per square millimeter was
calculated. In the case of ET-1 and CD31 double staining, we
determined the number of ET-1 positive cells in the dermis
and the percentage of positive ET-1 blood vessels on the total
number of blood vessels.
3. RESULTS
3.1. VascularstatusinCRPS
The qualitative diﬀerences between the distal and proximal
specimens are shown in Figure 1(a). These diﬀerences were
conﬁrmed by qualitative image analysis of the sections.
In both patients, endothelial immunoreactivity was more
prominent in distal than in proximal specimens. In patient
A, the mean number of CD31-IR capillaries in distal tissue
was 43 blood vessels/mm2 versus 14 blood vessels/mm2 in
proximaltissue;inpatientB,themeanswere39and19blood
vessels/mm2,r e s p e c t i v e l y .
3.2. eNOSimmunoreactivity
eNOS immunoreactivity of capillaries and other small-
diameterbloodvesselswasprominentinthedistalspecimens
(see Figure 1(b)). The measure of eNOS-IR endothelium in
patient A was 23 blood vessels/mm2 in distal tissue versus 7
bloodvessels/mm2 inproximaltissue;inpatientB,themeans
were 20 and 13 blood vessels/mm2,r e s p e c t i v e l y .
3.3. Ratios
The ratios of eNOS/CD31-IR vessels were similar. In patient
A, the mean ratios were 53% and 50% in distal and proximal
tissues, respectively, whereas in patient B, the mean ratios
were 51% and 68%, respectively.
3.4. Endothelin-1positivecells
The mean number of ET-1-positive cells was determined in
both the dermis and the blood vessels (Figure 2). In patient
A, there were 81 ET-1-positive dermis cells/mm2 in distal
tissue versus 22 ET-1-positive dermis cells/mm2 in proximal
tissue; in patient B, there were 42 and 12 ET-1-positive
dermis cells/mm2, respectively. The mean percentages ET-1-
positive blood vessels were similar; in patient A, there were
70% ET-1-positive blood vessels in the distal tissue and 69%
in the proximal tissue; in patient B, the mean values were
78% and 63%, respectively.4 Mediators of Inﬂammation
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Figure 2: Double staining for CD31 and ET-1 in skin tissue from
the amputated leg of CRPS patient B. CD31-positive blood vessels
are stained red and ET-1-positive cells are stained blue.
4. DISCUSSION
Because of the increased risk of an overreaction to a skin
biopsy [15], we could not take skin tissue samples from
CRPS-aﬀectedlimbsintheusualmanner.Therefore,weused
specimens taken from amputated limbs, which are seldom
available. Proximal and distal specimens from the amputated
leg or arm from two diﬀerent patients were dissected
out immediately after the amputation, and deep frozen in
liquid nitrogen. As specimens from the contra-lateral side
or healthy tissue were not available for comparison, we
considered the distal specimens as the most-aﬀected and the
proximal specimens as non- or least-aﬀected tissue. This is
the ﬁrst study that investigates the distribution of eNOS and
ET-1 in tissue of CRPS patients, therefore we decided to limit
the study to skin tissue, following previous observations in
skin blister ﬂuid obtained from CRPS patients. Expanding
the study to muscle and/or nerve tissue might have provided
additional insights in mechanisms underlying CRPS.
Tissue blood distribution is altered in patients with
CRPS. It is generally accepted that during the course of
this disease, and partly due to disuse, tissue ischemia
will occur, leading to chronic pain [24]. However, until
now, there was no evidence suggesting that these patients
have endothelial dysfunction or impaired angiogenesis in
response to ischemia. We observed regional diﬀerences
in the expression of endothelial markers in the CRPS-
aﬀected limbs. Information about the normal distribution of
these markers between proximal and distal upper or lower
extremities is not available. Expression of CD31, eNOS, and
ET-1 was highest in the distal specimens, representing the
most aﬀected samples of the diseased limbs. However, the
eNOS/CD31 ratios were similar, ranging from 51% to 68%.
Palatka et al. [25] reported an eNOS/CD31 ratio of 92% in
healthy mucosal biopsies, whereas this ratio was 8% in tissue
samples from patients with Crohn’s disease and 82% in sam-
ples from patients with ulcerative colitis, which suggests that
eNOS activity is diminished in disease-aﬀected endothelial
cells. Although values from mucosa may not be comparable
to the skin tissue values in our study, the suggestion is made
that eNOS activity was diminished in our patients, but not
dramatically. Moreover, we observed no distinct regional
diﬀerences, coinciding with the observations that during the
course of the disease, pain spreads through the entire limb
and that CRPS may also occur in the contra lateral limb
and/or the other extremities [26]. It has been shown that
during hypoxia, expression of both endothelial cell markers
CD31 and eNOS increases [27]. In the case of ischemia,
eNOS is essential for promoting collateral growth in order to
restore blood distribution to the tissues [28, 29]. Therefore,
in patients with CRPS, supplementing NO precursors will
not provide beneﬁt because eNOS activity is compromised.
Treating patients with chronic CRPS with an endothelium-
independent NO donor might be a more eﬀective strategy
[30].
Our data conﬁrmed the previously reported increase
in capillary density in CRPS-aﬀected tissue [11, 12], and
showedahighernumberofET-1-positivebloodvessels/mm2
in distal versus proximal specimens. There were marked
diﬀerences (3 to 4 fold) in the number of ET-1-positive cells
between the distal and proximal dermis. ET-1 promotes pro-
liferation and migration of endothelial cells via endothelin-
Br e c e p t o r s[ 31]. These migrated cells are associated with
swelling and laminal wall disruptions [13]. The pronounced
increase in ET-1 expression in the distal limbs conﬁrms
e a r l i e rw o r kb yo u rg r o u pi nw h i c hw ef o u n de l e v a t e dl e v e l s
of ET-1 in the superﬁcial blister ﬂuids harvested from the
distal region of CRPS limbs [24]. However, alterations in
the number of ET-1-positive cells and skin blister ﬂuid
concentrations do not necessarily reﬂect an increase in the
number of endothelin-B receptor-binding CD31-positive
endothelial cells [31]. Nevertheless, ET-1 blockers could
provide relief.
This study was limited to only two CRPS type 1 patients,
and lacks appropriate control in the form of contralateral
tissue, or a normal distribution of these markers. Both
patients were chronic and have been treated with many
medical and interventional procedures. Conclusions can
therefore only apply to potential mechanisms that maintain
chronic CRPS, like severe vasoconstriction, blood supply
redistribution due to abnormal blood ﬂow shunting with
hypoperfusion in nutritive vessels, hypoxia, lactate increase,
and acidosis [1].
In conclusion, we found an indication that endothelial
dysfunction plays a role in chronic CRPS. In comparison
to proximal specimens, we found an increased number of
m i g r a t e de n d o t h e l i a lc e l l sa sw e l la sa ni n c r e a s eo fe N O S
activity in distal dermis specimens.
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